» Articles » PMID: 39590138

Malignant Pleural Effusion: Diagnosis and Treatment-Up-to-Date Perspective

Overview
Journal Curr Oncol
Publisher MDPI
Specialty Oncology
Date 2024 Nov 26
PMID 39590138
Authors
Affiliations
Soon will be listed here.
Abstract

Malignant pleural effusion is the presence of malignant cells within the pleural fluid, representing the second most common cause of pleural exudate. Although diagnostic methods and management techniques for malignant pleural effusion have dramatically improved over the decades, the current treatment is still palliative, aiming to remove pleural fluid, possibly prevent its recurrence, and alleviate symptoms through a wide range of available procedures. Treatment should be tailored to the individual patient, considering comorbidities, size of the effusion, rate of fluid accumulation, underlying cardiac or respiratory conditions, rate of recurrence, presence of loculations or trapped lung, tumor characteristics, cancer type, and patient preferences. This manuscript aims to review the available literature and to present the latest evidence on malignant pleural effusion management in order to provide an updated perspective on its diagnosis and treatment.

Citing Articles

Potential utility of miRNAs derived from pleural fluid extracellular vesicles to differentiate between benign and malignant pleural effusions.

Chee T, Zahra C, Fong K, Yang I, Bowman R Transl Lung Cancer Res. 2025; 14(1):124-138.

PMID: 39958230 PMC: 11826272. DOI: 10.21037/tlcr-24-945.

References
1.
Lee Y, Baumann M, Maskell N, Waterer G, Eaton T, Davies R . Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists. Chest. 2003; 124(6):2229-38. DOI: 10.1378/chest.124.6.2229. View

2.
Porcel J, Hernandez P, Martinez-Alonso M, Bielsa S, Salud A . Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis. Chest. 2014; 147(2):502-512. DOI: 10.1378/chest.14-0820. View

3.
Gayen S . Malignant Pleural Effusion: Presentation, Diagnosis, and Management. Am J Med. 2022; 135(10):1188-1192. DOI: 10.1016/j.amjmed.2022.04.017. View

4.
Dresler C, Olak J, Herndon 2nd J, Richards W, Scalzetti E, Fleishman S . Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005; 127(3):909-15. PMC: 4644736. DOI: 10.1378/chest.127.3.909. View

5.
Lentz R, Lerner A, Pannu J, Merrick C, Roller L, Walston C . Routine monitoring with pleural manometry during therapeutic large-volume thoracentesis to prevent pleural-pressure-related complications: a multicentre, single-blind randomised controlled trial. Lancet Respir Med. 2019; 7(5):447-455. DOI: 10.1016/S2213-2600(18)30421-1. View